Intuitive Surgical (ISRG) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Intuitive Surgical

NasdaqGS•Healthcare•Medical Instruments & Supplies

$440.75+3.88(0.01%)After hours

Market Cap

$152.47B

P/E

51.6x

P/S

13.2x

P/B

9.5x

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

How this company scores

ExcellentMetricSide Score: 82/100

Strongest: Growth (23/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability21/25

Growth23/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality23/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 51.6x5y range 45.8x – 135.4x

Currently below its 20-quarter median.

P/S · 13.2x5y range 13.0x – 31.8x

Currently below its 20-quarter median.

P/B · 9.5x5y range 7.9x – 16.0x

Currently near its 20-quarter median.

Price & Volume

Market Cap $152.47B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $11.58B
Q. Revenue: $3.05B
TTM EBITDA: $4.04B
TTM Op. Income: $3.28B
Q. Op. Income: $592.60M
TTM Net Income: $2.96B
Q. Net Income: $522.80M
EPS: $1.5
Shares Out.: $349.00M

$11.58B in TTM revenue grew 20.5% YoY, reaching $3.05B last quarter. TTM EBITDA of $4.04B and TTM operating income of $3.28B show growth is flowing through to the bottom line. TTM net income of $2.96B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 68.4%
EBITDA Margin: 25.9%
Op. Margin: 19.4%
Net Margin: 17.1%

Op. margin of 19.4% is down 10.9% YoY — costs are rising relative to revenue. Net margin at 17.1% and gross margin of 68.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 36% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 51.6x
P/S Ratio: 13.2x
P/B Ratio: 9.5x

At 51.6x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 13.2x and P/B of 9.5x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 10% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $19.35B
Cash: $2.98B
Long-Term Debt: N/A
Book Value: $16.12B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.22B
TTM Free Cash Flow: $3.60B
FCF Margin: 31.1%
FCF / Net Income: 1.2

TTM FCF of $3.60B on $1.22B in operating cash flow. The FCF / Net Income ratio of 1.2x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.